Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes... Show more
LNTH is expected to report earnings to fall 11.64% to $1.29 per share on July 30
Q2'26
Est.
$1.29
Q1'26
Beat
by $0.23
Q4'25
Beat
by $0.51
Q3'25
Missed
by $0.01
Q2'25
Missed
by $0.10
The last earnings report on May 07 showed earnings per share of $1.46, beating the estimate of $1.23. With 386.16K shares outstanding, the current market capitalization sits at 7.15B.